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Summary
Objective: To determine the predictors of fatality among patients with Crimean-Congo hemor-
rhagic fever (CCHF) based on epidemiological, clinical, and laboratory findings.
Methods: Among the patients with possible CCHF who were referred to Ankara Numune Educa-
tion and Research Hospital (ANERH) from the surrounding hospitals between 2003 and 2006, those
with IgM antibodies and/or reverse transcriptase-polymerase chain reaction (RT-PCR) results
positive for CCHF virus in their blood, and who had received only supportive treatment, were
included in the study.
Results: Sixty-nine patients with CCHF were admitted to ANERH from various cities of the
northeastern part of the central region and southern parts of the Black Sea region of Turkey.
Eleven (15.9%) patients died. Age, gender, days from the appearance of symptoms to admission,
and initial complaints except bleeding were similar between fatal and non-fatal cases ( p > 0.05).
Among the clinical findings, ecchymosis (p = 0.007), hematemesis (p = 0.030), melena
(p < 0.001), somnolence (p < 0.001), and gingival bleeding ( p = 0.044) were more common
among fatal cases. The mean platelet count was 47.569  109/l in non-fatal cases and
12.636  109/l in fatal cases (p = 0.003). Among the fatal cases, the mean prothrombin time
(PT; 18.4 s vs. 13.4 s; p < 0.001) and the mean activated partial thromboplastin time (aPTT;
69.4 s vs. 42.7 s; p = 0.001) were longer, and the mean alanine aminotransferase (ALT; 1688 vs.
293; p < 0.001), mean aspartate aminotransferase (AST; 3028 vs. 634; p < 0.001), mean lactate
dehydrogenase (LDH; 4245 vs. 1141; p < 0.001), mean creatine phosphokinase (CPK; 3016 vs. 851;
p = 0.004) levels and the mean international normalized ratio (INR; 1.38 vs. 1.1; p < 0.001) were
higher. In a Cox proportional hazards model, thrombocytopenia of 20  109/l (hazard rate (HR)
9.67; 95% confidence interval (CI) 1.16—80.68; p = 0.036), a prolonged aPTT60 s (HR 11.62; 95%
CI 2.40—56.27; p = 0.002), existence of melena (HR 6.39; 95% CI 1.64—24.93; p = 0.008), and
somnolence (HR 6.30; 95% CI 1.80—22.09; p = 0.004) were independently associated with
mortality.
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Conclusions: Thrombocytopenia of 20  109/l, a prolonged aPTT 60 s, the existence of melena,
and somnolence were independent predictors of fatality.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Crimean-Congo hemorrhagic fever (CCHF) is caused by a
Nairovirus belonging to the genus Bunyavirus of the family
Bunyaviridae, and transmitted to humans by Hyalomma ticks
or by direct contact with the blood of infected humans or
domestic animals.1,2 The most common clinical signs of CCHF
are fever, nausea, headache, diarrhea, myalgia, petechial
rash, and bleeding.3
At present, CCHF is a public health problem in many
regions of the world including Asia, Eastern Europe, Africa,
and Russia.4 CCHF is a severe disease in humans with a
fatality rate of up to 80%, most deaths occurring 5 to 14
days after the onset of illness.3—5 Since 2002, a rapid emer-
gence of CCHF has occurred in the central, northern, and
eastern regions of Turkey.6—8 By the end of 2006, there had
been 1103 confirmed CCHF cases and 59 (5.4%) deaths in
Turkey.9
This study was undertaken to determine the predictors of
fatality among patients with CCHF based on epidemiological,
clinical, and laboratory findings.
Methods
This prospective study was carried out at Ankara Numune
Education and Research Hospital (ANERH), a referral and
tertiary-care hospital in Turkey. Several patients with possi-
ble CCHF were referred to ANERH from the surrounding
hospitals during the spring and summer seasons of the years
2003 to 2006. Only patients with a definitive diagnosis of
CCHF by means of clinical presentation plus the presence of
specific IgM antibody and/or detection of viral RNA by reverse
transcriptase-polymerase chain reaction (RT-PCR), and
patients who had received only supportive treatment, were
included in the study. Biochemical and hematological labora-
tory parameters were measured on a daily basis after admis-
sion to the hospital. Data were recorded prospectively on
individual forms.
Patients were given preparations of erythrocytes, plate-
lets, and fresh frozen plasma depending on their homeostatic
state. Patients who received antiviral therapy were excluded
from the study as antiviral therapy might have changed the
course of the disease.
Statistical analysis
The Student’s t-test was used for independent and paired
continuous variables, and proportion comparisons for cate-
gorical variables were done using Chi-square tests, although
Fisher’s exact test was usedwhen data were sparse. A p-value
of <0.05 was considered statistically significant. Survival
curves with a 95% confidence interval were computed using
the Kaplan—Meier method. Cox regression was used to model
outcomes. The time start-point was the onset of complaintsand the time end-point was either death or discharge from
the hospital. For multivariate analysis, only variables with a p
value <0.05 were entered into a Cox proportional hazards
model and selected using a stepwise selection procedure.
Hazard ratios (HR) and 95% confidence intervals (95% CI) were
computed from estimated parameters of the final regression
model. Software package Stata 9.0 (College station, Texas,
USA) was used for the analysis.
Results
Sixty-nine patients were enrolled in the study. These patients
were from various cities of the northeastern part of the
central region and southern parts of the Black Sea region
of Turkey. Their mean age was 50 years, and 45 patients
(65.2%) were male. Fifty-four (78.3%) patients were involved
in farming/handling livestock. A history of tick bite was
present for 37 (53.6%) patients.
The patients showed hemorrhagic signs including epis-
taxis (26.1%), petechiae (20.3%), ecchymosis (17.4%),
melena (17.4%), gingival bleeding (15.9%), hematemesis
(13.0%), hematuria (5.8%), and hematoma (2.9%). Other
prominent clinical signs were fever, anorexia, myalgia,
and headache. Almost all of the patients had leukopenia,
thrombocytopenia, and elevated aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), lactate dehydro-
genase (LDH), and creatine phosphokinase (CPK) levels at
the time of admission.
Forty patients were IgM positive and 50 patients were RT-
PCR positive. Seven (63.6%) out of the 11 fatal cases were
only RT-PCR positive.
The case—fatality rate was 15.9%. Fatal cases were hos-
pitalized for a mean of 3.8 days (range 1—9) before death.
The duration of hospitalization was approximately 8 days
(range 2—19) in non-fatal cases. The disease started a mean
of 6.3 days (range 2—10) before hospitalization in fatal cases
and 5.8 days (range 1—15) in non-fatal cases.
Age, gender, number of days from the appearance
of symptoms to admission, and initial complaints except
bleeding were similar between fatal and non-fatal cases
( p > 0.05). Among the clinical findings, ecchymosis
( p = 0.007), hematemesis ( p = 0.030), melena ( p < 0.001),
somnolence ( p < 0.001), and gingival bleeding ( p = 0.044)
were more common among fatal cases (Table 1).
In fatal cases, the mean heart rate was 89 bpm (range 80—
112) and in non-fatal cases 86 bpm (range 62—120)
( p = 0.483). Blood pressure was normal in all patients at
the time of admission.
The mean platelet count was 47.569  109/l in non-fatal
cases and 12.636  109/l in fatal cases ( p = 0.003). Among
the fatal cases the mean prothrombin time (PT; 18.4 s vs.
13.4 s; p < 0.001) andmean activated partial thromboplastin
time (aPTT; 69.4 s vs. 42.7 s; p = 0.001) were longer, and the
mean ALT (1688 vs. 293; p < 0.001), mean AST (3028 vs. 634;
p < 0.001), mean LDH (4245 vs. 1141; p < 0.001), mean CPK
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Table 1 Univariate analysis of demographic and clinical variables for non-fatal and fatal cases with Crimean-Congo hemorrhagic
fever
Characteristic Non-fatal cases (N = 58) Fatal cases (N = 11) p Value
Age, years 49.1  16.7 53.5  17.4 0.435
Female sex 19 (32.8%) 5 (45.5%) 0.418
Duration of complaints until hospitalization, days 5.8  2.7 6.3  2.6 0.574
Most common complaints
Myalgia 50 (86.2%) 10 (90.9%) 0.560
Fever 49 (84.5%) 10 (90.9%) 0.315
Lack of appetite 47 (81.0%) 10 (90.9%) 0.385
Headache 39 (67.2%) 6 (54.5%) 0.418
Nausea and/or vomiting 29 (50%) 6 (54.5%) 0.782
Bleeding (any kind) 16 (27.6%) 9 (81.8%) 0.001
Diarrhea 11 (19.0%) 3 (27.3%) 0.393
Cough 9 (15.5%) 1 (9.1%) 0.498
Clinical findings
Fever, temperature >38 8C 29 (50%) 6 (54.5%) 0.782
Hepatomegaly 10 (17.2%) 3 (27.3%) 0.341
Splenomegaly 6 (10.3%) 1 (9.1%) 0.691
Jaundice 3 (5.2%) 1 (9.1%) 0.509
Rash
Maculopapular 3 (5.2%) 2 (18.2%) 0.177
Petechiae 10 (17.2%) 4 (36.4%) 0.150
Bleeding
Ecchymosis 7 (12.1%) 5 (45.5%) 0.007
Hematoma 0 2 (18.2%) —
Epistaxis 14 (24.1%) 4 (36.4%) 0.308
Hematemesis 5 (8.6%) 4 (36.4%) 0.030
Melena 4 (6.9%) 8 (72.7%) <0.001
Hematuria 2 (3.4%) 2 (18.2%) 0.117
Gingival 7 (12.1%) 4 (36.4%) 0.044
Vaginal 2 (3.4%) 0 —
Somnolence 2 (3.4%) 6 (54.5%) <0.001(3016 vs. 851; p = 0.004) levels and the mean international
normalized ratio (INR; 1.38 vs. 1.1; p < 0.001) were higher
(Table 2).
All patients received intensive clinical support, including
platelets, fresh frozen plasma, and packed erythrocyte infu-
sions when indicated. None of the patients received antiviralTable 2 Univariate analysis of laboratory findings for non-fatal a
Laboratory finding Non-fatal cases Mean
Lowest platelet count (platelets  109/l) 47.569 (4.00—183.
Lowest WBC count (WBC  109/l) 2.084 (0.70—6.00
Highest AST level, U/l 634 (17—4202)
Highest ALT level, U/l 293 (18—1278)
Highest LDH level, U/l 1141 (257—9237)
Highest CPK level, U/l 851 (150—7150)
Longest PT, s 13.4 (10.2—18.1)
Longest aPTT, s 42.7 (25.8—154)
Highest INR 1.1 (0.8—1.6)
Lowest fibrinogen, mg/dl 240 (115—389)
WBC, white blood cell.
Normal ranges: aspartate aminotransferase (AST), 5—34 U/l; alanine am
243 U/l; creatine phosphokinase (CPK), 25—200 U/l; prothrombin time
20—34 s; international normalized ratio (INR), 0.8—1.2; fibrinogen, 18therapy. Fatal cases received significantly more fresh frozen
plasma (14 vs. 2 packs, p < 0.001) and platelet suspensions
(26 vs. 8 packs, p = 0.017) than non-fatal cases.
The Cox proportional hazards model was used for fatality
analysis. The time start-point was the onset of complaints
and time end-point was either death or discharge from thend fatal cases with Crimean-Congo hemorrhagic fever
value (range) Fatal cases Mean value (range) p Value
00) 12.636 (4.00—34.00) 0.003
) 2.494 (1.10—6.52) 0.328
3028 (278—11 870) <0.001
1688 (193—7345) <0.001
4245 (473—7866) <0.001
3016 (216—16 372) 0.004
18.4 (13.1—39.8) <0.001
69.4 (42.8—85.9) 0.001
1.38 (1—1.9) <0.001
198 (108—424) 0.121
inotransferase (ALT), 0—55 U/l; lactate dehydrogenase (LDH), 123—
(PT), 11.5—15.5 s; activated partial thromboplastin time (aPTT),
0—350 mg/dl.
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Table 3 Estimated regression coefficient, standard error, p value, and hazard ratio as a function of the risks of the variables
according to the Cox proportional hazards model
Variables Coefficient Standard error p Value Hazard ratio (95% CI)
Activated partial thromboplastin time 60 s 3.05 9.35 0.002 11.62 (2.40—56.27)
Platelet count 20  109/l 2.10 10.46 0.036 9.67 (1.16—80.68)
Melena 2.67 4.44 0.008 6.39 (1.64—24.93)
Somnolence 2.87 4.03 0.004 6.30 (1.80—22.09)hospital. Thrombocytopenia of20  109/l (hazard rate (HR)
9.67; 95% confidence interval (CI) 1.16—80.68; p = 0.036), a
prolonged aPTT 60 s (HR 11.62; 95% CI 2.40—56.27;
p = 0.002), the existence of melena (HR 6.39; 95% CI 1.64—
24.93; p = 0.008), and somnolence (HR 6.30; 95% CI 1.80—
22.09; p = 0.004) were independently associated with mor-
tality (Table 3, Figures 1—4).
Discussion
CCHF virus causes a fatal hemorrhagic syndrome, which has
been endemic in the central, northern, and eastern regions of
Turkey in recent years. CCHF is an acute and generally self-
limiting disease. Clinically, CCHF results in the most severe
bleeding and ecchymoses among the hemorrhagic fevers.
Hemorrhagic manifestations include gingival bleeding and
epistaxis followed by gastrointestinal hemorrhage. Ecchy-
moses are often large and pressure-linked.10 The clinical
presentation of patients with CCHF in this study was similarFigure 1 Kaplan—Meier survival estimates by somnolence,
time from onset of complaints to death or discharge.
Figure 2 Kaplan—Meier survival estimates by melena, time
from onset of complaints to death or discharge.to that reported previously.10,11 On admission, the most fre-
quently detected symptoms were fever, myalgia, lack of
appetite, headache, nausea/vomiting, and bleeding. In this
study, 58% of patients had bleeding symptoms. Epistaxis
(26.1%) was the most frequently observed hemorrhagic man-
ifestation followed by petechiae (20.3%), ecchymosis (17.4%),
melena (17.4%), gingival bleeding (15.9%), hematemesis
(13.0%), hematuria (5.8%), and hematoma (2.9%). Although
it has been reported that cardiovascular changes including
bradycardia and low blood pressure can be seen,12 none of our
patients had signs of cardiovascular abnormalities.
Various fatality rates for CCHF, of up to 80%, have been
reported in the literature.1,3,11,13 In this study, a fatality rate
of 15.9% was obtained, which is higher than the average for
Turkey (5.4%) and previously reported fatality rates.8,13,14
The fatality rate reported by the Ministry of Health of Turkey
includes all CCHF cases including the ones treated in primary-
and secondary-care services. As ANERH is a referral and
tertiary-care hospital, more complicated and severe casesFigure 3 Kaplan—Meier survival estimates by platelet count,
time from onset of complaints to death or discharge.
Figure 4 Kaplan—Meier survival estimates by activated partial
thromboplastin time, time from onset of complaints to death or
discharge.
378 M.A. C¸evik et al.are transferred here from the surrounding hospitals; hence,
the high fatality rate obtained in this study is probably due to
the admission of severe cases. On the other hand, high death
rates reported in some series in contrast to the lower fatality
rates in our patients can be explained by the wide availability
of blood products at our institution compared to other facil-
ities, and also to better supportive care of our patients.
Deaths are reported to occur on days 5—14 of CCHF.15 In
this study, the mean duration from the onset of complaints
until death was 10.2 days (range 3—19 days).
In fatal cases there was little evidence of an antibody
response.16 In seven out of 11 fatal cases no serum IgM or IgG
was detected although the virus was identified by PCR. The
absence of a significant antibody response in fatalities has
been reported previously.17
Any of the following clinical pathologic values during the
first 5 days of illness were found to be >90% predictive of
fatal outcome in a series of South African CCHF patients:
leukocyte counts < 10  109/l, platelet counts <20  109/l,
AST >200 U/l, ALT >150 U/l, aPTT >60 s, and fibrinogen
<110 mg/dl.17 Other case series have confirmed that levels
of AST and ALT are significantly higher among severe cases
( p < 0.05).8,13,14 In a study from Turkey, higher AST and ALT
levels (>700 and>900 IU/l, respectively) were found to have
higher sensitivity for severe cases.14
Previously defined severity criteria did not completely fit
the patients in the present study (Table 4).14,17 Leukocytosis
wasoneof the fatality criteriadescribedbySwanepoeletal.,17
but this was only observed in one fatal case and two non-fatal
cases in our study. Decreased fibrinogen of 110 mg/dl was
another previously described fatality criterion that was
observed only in one patient in our study. In contrast to
Swanepoel et al.,17 we observed no renal failure. An aPTT
of>60 s (HR 11.62; 95%CI 2.40—56.27; p = 0.002)was found to
be an independent predictor of fatality in the present study.
Themean platelet count was 47.569  109/l in non-fatal cases
and 12.636  109/l in fatal cases (p = 0.003).We found throm-
bocytopenia of 20  109/l (HR 9.67; 95% CI 1.16—80.68;
p = 0.036) to be a strong independent predictor of fatality.
Among the fatal cases, themean ALT (1688 vs. 293; p < 0.001)
and themean AST (3028 vs. 634; p < 0.001) levelswere higher.Table 4 Comparison of predictors of fatality with previously rep
Criteria Swanepoel et al. 17
Increased WBC count, 10  109/l Yes
Decreased platelet count, 20  109/l Yes
Elevated AST level Yes
Elevated ALT level Yes
Elevated LDH level No
Elevated CPK level No
Prolonged aPTT Yes
Prolonged PT No
Decreased fibrinogen, 110 mg/dl Yes
Ecchymosis No
Melena No
Hematemesis No
Somnolence No
AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH
thrombin time; aPTT, activated partial thromboplastin time.Most of our patients had at least one or more risk factors as
described above; however, the overall death rate was 15.9%.
Further observations with larger numbers of patients are
necessary to clarify these inconsistencies.
Bakir et al. reported that the INR, AST, LDH, and CPK levels
were higher in patients with a fatal outcome.8 In this study
fatal cases had higher AST, LDH and CPK levels, and a higher
INR.
Among the clinical findings, melena and hematemesis
were more commonly reported among fatal cases.14 In this
study all of the fatal cases had hematemesis and/or melena.
Additionally, the risk of fatality was higher in patients with
melena (HR 6.39; 95% CI 1.64—24.93; p = 0.008).
An altered mental status (such as unconsciousness, con-
fusion, and somnolence) has previously been reported as an
indicator of poor prognosis.8,13,14 In the present study, the
existence of somnolence (HR 6.30; 95% CI 1.80—22.09;
p = 0.004) showed a strong relationship with the severity
of illness and subsequent probability of death.
Treatment options for CCHF are limited. Supportive ther-
apy is the most essential part of case management and
includes intensive monitoring to guide volume and adminis-
tration of platelets, fresh frozen plasma, and erythrocyte
preparations.12,13 Currently, there is no specific antiviral
therapy for CCHF approved for use in humans. However,
some reports have been published that suggest that oral or
intravenous ribavirin is effective for treating CCHF infec-
tions.6,18,19 In another study from Turkey, it was highlighted
that oral ribavirin treatment did not decrease the need for
blood and its products and did not have any effect on redu-
cing the fatality rates.13 It is important to mention that there
have been no randomized or controlled studies to confirm the
effectiveness of ribavirin against CCHF to date. Therefore,
the efficacy of ribavirin in the treatment of CCHF is not clear.
Immunotherapy has been attempted via passive transfer of
CCHF survivor convalescent plasma,20 but its value is also not
clear. There is an urgent need to establish effective treat-
ment(s) for CCHF.
To conclude, from the results of our study we report that
the most important risk factors for fatality in CCHF are the
existence of somnolence and melena, a prolonged aPTTorted criteria (data extracted from univariate analysis)
Ergonul et al. 14 Present study p Value
No No 0.400
Yes Yes 0.035
Yes Yes <0.001
Yes Yes <0.001
No Yes <0.001
No Yes 0.004
Yes Yes 0.001
Yes Yes <0.001
Yes No 0.121
No Yes 0.007
Yes Yes <0.001
Yes Yes 0.030
Yes Yes <0.001
, lactate dehydrogenase; CPK, creatine phosphokinase; PT, pro-
Clinical and laboratory features of CCHF 379(60 s), and a decreased platelet count (20  109/l). We
suggest that such patients should be observed more carefully
for intensive supportive therapy.
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